Including Tecentriq to chemo resulted in survival outcomes similar to placebo plus chemo in sufferers with superior or recurrent endometrial most cancers, in response to outcomes from the section 3 AtTEnd/ENGOT-EN7 trial offered on the 2025 ESMO Congress.
Including Tecentriq (atezolizumab) to chemotherapy resulted in survival outcomes similar to placebo plus chemotherapy in sufferers with superior or recurrent endometrial most cancers, in response to outcomes from the section 3 AtTEnd/ENGOT-EN7 trial offered on the 2025 ESMO Congress.
After a median follow-up of 48.9 months, general survival (OS) didn’t considerably differ between sufferers handled with Tecentriq versus placebo, with a median of 36 months versus 30.5 months, respectively. The respective 12- and 24-month OS charges had been 80.1% versus 73.8% and 61.1% versus 58.4%. Moreover, 12.1% of sufferers within the Tecentriq arm versus 29.2% within the placebo arm obtained subsequent immunotherapy.
In a deliberate subgroup evaluation primarily based on mismatch restore poor (dMMR) standing, sufferers with dMMR illness skilled considerably improved OS with Tecentriq. Median OS was not evaluable within the Tecentriq arm versus 31.8 months with placebo; 12- and 24-month charges had been 86.8% versus 66.8% and 74.8% versus 54.8%. Subsequent immunotherapy was obtained by 7.4% versus 45.5% of sufferers in every respective arm.
Amongst sufferers with non-dMMR standing, survival outcomes didn’t considerably differ. Median OS was 30 months with Tecentriq versus 30.2 months with placebo; 12- and 24-month charges had been 77.8% versus 75.8% and 55.9% versus 58.8%. Subsequent immunotherapy was obtained by 13.8% versus 24.3% of sufferers, respectively.
Development-free survival (PFS) outcomes numerically favored Tecentriq throughout all sufferers. Median PFS was 9.9 months versus 8.9 months, with 12- and 24-month charges of 44.7% versus 28.9% and 28.7% versus 16.8%. Amongst sufferers with dMMR illness, median PFS was not evaluable versus 6.9 months, with 12- and 24-month charges of 62.7% versus 23.3% and 52.1% versus 16.3%. In non-dMMR sufferers, median PFS was 9.5 months versus 9.2 months, with 12- and 24-month charges of 39.1% versus 30.2% and 21.7% versus 16.0%.
Glossary
Total survival (OS): The size of time sufferers are nonetheless alive after beginning remedy.
Development-free survival (PFS): The size of time sufferers stay with out most cancers getting worse.
Mismatch restore poor (dMMR): A genetic characteristic of some cancers the place cells can’t repair DNA errors correctly, making tumors extra aware of immunotherapy.
Goal response charge (ORR): The share of sufferers whose tumors shrink or disappear after remedy.
Full response (CR): The disappearance of all indicators of most cancers.
Partial response (PR): A major discount in tumor measurement however not full disappearance.
Length of response (DOR): How lengthy a affected person’s tumor stays decreased or gone after remedy.
ECOG efficiency standing: A scale (0-5) that measures a affected person’s each day functioning and skill to look after themselves.
Goal response charge (ORR) and period of response (DOR) in dMMR sufferers numerically favored Tecentriq. ORR was 82.4% with an entire response (CR) charge of 26.5% and a partial response (PR) charge of 55.9%, versus 75.7% with a CR charge of 18.9% and a PR charge of 56.8% with placebo. Median DOR was not evaluable versus 4.9 months, with 12- and 24-month charges of 66.9% versus 22.3% and 57.6% versus 14.8%. In non-dMMR sufferers, ORR was 75.6% versus 74.6%, with CR and PR charges of 15.1% and 60.5% versus 10.5% and 64.0%. Median DOR was 7.8 months versus 7 months, with 12- and 24-month charges of 35.1% versus 29.8% and 19.9% versus 15.0%.
“The addition of Tecentriq to chemotherapy didn’t display a statistically vital survival profit in sufferers with superior or recurrent endometrial carcinoma,” mentioned Dr. Maria Pilar Barretina Ginesta. “Within the pre-planned subgroup evaluation primarily based on mismatch restore standing, substantial survival enchancment was noticed in sufferers with dMMR carcinomas.”
The examine enrolled sufferers with superior newly recognized or recurrent endometrial carcinoma or carcinosarcoma and randomly assigned them to obtain paclitaxel and carboplatin space with Tecentriq or matching placebo. Following chemotherapy, sufferers obtained Tecentriq as upkeep or matching placebo.
Sufferers had been stratified by nation, histology, recurrent standing, and dMMR standing. Twin main finish factors had been PFS and OS.
Amongst all sufferers within the Tecentriq (360) and placebo (189) arms, 22.5% versus 23.3% had dMMR standing. Recurrent illness standing was 67.5% versus 66.7%, and 70.6% versus 68.2% had not obtained prior chemotherapy. In newly recognized illness, 75.2% versus 85.7% had measurable illness. Median age was 67 versus 65 years, and most sufferers had been Caucasian (80.3% versus 75.7%), PD-L1–unfavourable (68.6% versus 68.2%), and had intact ARID1A expression (68.9% versus 69.3%).
Any-grade negative effects occurred in 98.6% versus 100%, with 75.8% versus 63.8% associated to Tecentriq versus placebo. Grade 3 or increased negative effects had been noticed in 26.4% versus 14.1%, with deadly negative effects in 0.3% versus 0.5%. The commonest negative effects within the Tecentriq versus placebo arms had been anemia (41.3% versus 35.1%), fatigue (39% versus 41.1%), neutropenia (40.7% versus 39.5%), peripheral sensory neuropathy (38.8% versus 39.5%), nausea (34% versus 37.3%), and hair loss (31.5% versus 36.2%).
Reference
- “Ultimate general survival (OS) outcomes from the randomized double-blind section III AtTEnd/ENGOT-EN7 trial evaluating atezolizumab together with paclitaxel and carboplatin in girls with superior/recurrent endometrial most cancers,” by Dr. Maria Pilar Barretina Ginesta. Introduced on the European Society for Medical Oncology (ESMO) Congress 2025; October 17-21, 2025; Berlin, Germany. Summary LBA39.
For extra information on most cancers updates, analysis and training,
